Clinical Trial Update: Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 bioequivalence study of lamotrigine 25 mg tablets under fed conditions conducted by IPCA Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• Lamotrigine (lamotrigine)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fed | Phase 1 | Status: COMPLETED